Safety

Betaseron (Interferon Beta-1b) For Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

April 2016

Summary View

WARNINGS AND PRECAUTIONS

Drug-induced Lupus Erythematosus
  • Cases of drug-induced lupus erythematosus have been reported with some interferon beta products, including BETASERON. Signs and symptoms of drug-induced lupus reported in BETASERON-treated patients have included rash, serositis, polyarthritis, nephritis, and Raynaud’s phenomenon. Cases have occurred with positive serologic testing (including positive anti-nuclear and/or anti-double-stranded DNA antibody testing). If BETASERON-treated patients develop new signs and symptoms characteristic of this syndrome, BETASERON therapy should be stopped.

 

December 2012

Summary View 

ADVERSE REACTIONS

Postmarketing Experience
  • The following adverse reactions have been identified during postapproval use of Betaseron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure…

 

Page Last Updated: 05/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.